Brightmoor Hospice, LLC Provides Notification of Data Security Incident

GRIFFIN, Ga., Oct. 16, 2026 /PRNewswire/ -- Brightmoor Hospice, LLC ("Brightmoor") is providing notification of a data security incident that may have impacted certain protected health information.

On or around March 25, 2026, Brightmoor Hospice, LLC ("Brightmoor") discovered suspicious activity related to two employees' email accounts. Upon discovery, Brightmoor took immediate action to secure the accounts and engaged a team of third-party specialists to investigate. The investigation determined that two employee email accounts were accessed without authorization between March 24, 2026, and March 25, 2026. Upon confirmation of unauthorized access, Brightmoor began a comprehensive review of the contents of the affected accounts to determine whether they contained sensitive information pertaining to individuals. On August 18, 2026, Brightmoor determined that protected health information belonging to certain patients was present within the accounts. Brightmoor then conducted a time-intensive review of its internal records to locate address information for the potentially impacted individuals. On October 16, 2026, Brightmoor began notifying individuals by mail.

The types of information vary by individual and may include name and one or more of the following: addresses, Social Security numbers, driver's license information, dates of birth, patients' identification numbers, diagnosis, medical history information, medical record numbers, medical treatment information, lab information, treating doctor's name, medication information, vaccination information, medical insurance information, and family and social history information.

In response to this incident, Brightmoor worked with third-party specialists to investigate and implement additional security measures within its network. Brightmoor has no evidence of actual or attempted misuse of information as a result of this incident. Nonetheless, in an abundance of caution, Brightmoor is providing notice to potentially affected individuals and offering complimentary credit monitoring services. Individuals are also encouraged to monitor their account statements and explanation of benefits forms for suspicious activity and to detect errors. In addition, Brightmoor has notified the U.S. Health and Human Services Office for Civil Rights of this incident.

Brightmoor has established a toll-free call center to answer questions about the incident and to address related concerns. The number for the hotline is 1-800-759-8524. The hotline hours of operation are Monday through Friday from 8 AM to 8 PM EST, excluding holidays. You can also write to 3247 Newnan Rd, Griffin, GA 30223.

Brightmoor takes protecting the privacy and security of personal information seriously and is reviewing and implementing further security enhancements designed to strengthen the protection of our systems.

SOURCE Brightmoor Hospice, LLC

Share this article

NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.

Get Help

Chemours investors should visit us at https://claimsfiler.com/cases/nyse-cc-3/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."

On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler

Share this article

NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- - ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.

Get Help

Hims & Hers investors should visit us at https://claimsfiler.com/cases/nyse-hims-1/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Hims & Hers Health and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 29, 2026, during market hours, the Federal Trade Commission ("FTC") announced that it had filed a lawsuit against the Company "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." The FTC further alleged that the Company fails to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'"

On this news, the price of Hims & Hers Health shares fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026, on unusually heavy trading volume.

The case is Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

(833) 538-3604

SOURCE ClaimsFiler

Share this article

NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company's common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California.

Get Help

Beta Bionics investors should visit us at https://claimsfiler.com/cases/nasdaq-bbnx/ or call toll-free (833) 538-3604. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Beta Bionics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) the Company's sole commercialized device, the iLet Bionic Pancreas insulin pump ("iLet"), employed an aggressive automated dosing algorithm that malfunctioned and delivered dangerously high levels of insulin, causing hypoglycemic events, including hundreds of life-threatening events requiring medical intervention and hospitalization; (ii) the Company had received thousands of related customer complaints that it failed to investigate or timely report to the U.S. Food and Drug Administration ("FDA"); (iii) the FDA Form 483 issued to the Company in June 2025 identified more than 18,000 unreported complaints and was not, as Defendants represented, limited to a minor difference in interpretation of which complaints were reportable; (iv) the Company had failed to implement meaningful corrective actions in response to the Form 483, resulting in an FDA warning letter concerning the Company's quality management system, medical device reporting, and corrections and removals; and (v) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

The case is Holtzman v. Beta Bionics, Inc., et al., No. 26-cv-09999.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

(833) 538-3604

SOURCE ClaimsFiler

Share this article

EVIDENT Expands Its Pramana Digital Pathology Portfolio to Support Small and Medium-Sized Labs

The new Pramana™ POD benchtop WSI scanner delivers autonomous imaging to help laboratories create pathologist-ready whole slide images with minimal operator intervention.

NEEDHAM, Mass., Oct. 17, 2026 /PRNewswire/ -- Today, Evident announced the Pramana™ POD whole slide imaging (WSI) scanner, a new benchtop system designed to help laboratories produce trusted images. Built for small and medium-sized laboratories and specialty applications within larger institutions, the scanner helps make digital pathology adoption more accessible.

As pathology laboratories expand digital workflows amid increasing case volumes and operational demands, they need scanning systems that produce consistent, high-quality images across specimen types while integrating into existing laboratory workflows. Evident designed the Pramana POD scanner to address those needs, extending proven Pramana autonomous WSI technology to smaller laboratories.

"Pramana WSI technology has received tremendous acceptance from pathology labs across academic medical centers and network labs across the United States," said Prasanth Perugupalli, Vice President of Digital Pathology, Evident. "By incorporating quality assurance into the whole slide imaging process, Pramana technology can help labs of varying sizes reduce the need for post-scan QA and the associated costs and delays."

The Pramana POD scanner automates imaging with an advanced tissue finder, extensive label detection, and automated focal plane and scan-profile selection. Built-in image-quality assessment helps deliver pathologist-ready whole slide images and identify scans that may require further review. Volumetric imaging captures multiple focal planes to support the selection of sharp focal information across the scanned area, with true 40X imaging at 25 slides per hour under defined conditions.

The Pramana series of autonomous WSI scanners is well-suited for most brightfield imaging applications, including histopathology, core biopsies, hematology, cytology, and microbiology.

"Scientific advances move quickly, but laboratory infrastructure changes slowly," Perugupalli added. "With the Pramana POD scanner, small and medium-sized labs can build as their needs evolve."

To learn more about the Pramana POD benchtop WSI scanner, visit evidentscientific.com/products/slide-scanners/pramana-pod.

About EVIDENT

For over 100 years as Olympus, we set the industry standard for optical precision in microscopy, helping the world see what was once out of view. Today, as Evident, we continue to help scientists, physicians, and engineers illuminate the unseen with advanced imaging solutions that combine renowned optics with cutting-edge digital innovation.

Our life science portfolio supports research, clinical diagnostics, and education, offering a comprehensive range of imaging methods from essential brightfield and darkfield microscopy to advanced fluorescence, 4D analysis, and digital pathology. In industrial microscopy, we deliver precision and flexibility through laser scanning, digital, and semiconductor microscopes designed for tasks ranging from routine inspection to intricate quality control and manufacturing analysis.

Whether advancing new therapies, ensuring product integrity, or exploring the unknown, Evident is defining a new era of discovery with easy-to-use tools that help unlock hidden answers and empower exciting new breakthroughs.

Evident is headquartered in Tokyo and supported by R&D and manufacturing centers in Japan, the United States, Germany, and China, with operations and dedicated sales and service centers around the world. For more information, visit EvidentScientific.com.

For Research Use Only. Not for use in diagnostic procedures. Future clinical availability is subject to applicable regulatory authorization, and regulatory status and availability may vary by country. Performance varies by specimen type and workflow.

Pramana is a trademark of Evident Corporation or its subsidiaries.

Share this article

WASHINGTON, Oct. 16, 2026 /PRNewswire/ -- National Press Club President Mark Schoeff Jr. released the following statement today:

"The National Press Club condemns the attack on Washington Post photographer Heidi Levine.

Levine was viciously assaulted while doing exactly what an independent reporter is supposed to do – bearing witness to events unfolding in the West Bank. We're glad to hear she is receiving the medical attention she needs.

Journalists should never be targets in areas of conflict or anywhere else. A free and independent press cannot function properly under the threat of violence.

The Israeli government must conduct a full investigation into the incident and hold those responsible accountable. A brazen attack like this cannot go unanswered. If it does, it could put other journalists at risk by encouraging additional violence against the media."

About The National Press Club

Founded in 1908, the National Press Club is the world's leading professional organization for journalists and a leading voice for press freedom in the U.S. and worldwide.

Contact: Dan Griffin, Communications Director of the National Press Club, [email protected]

SOURCE National Press Club

Share this article

After reaffirming FY2026 guidance in May and raising it in August, Fox Factory cut its full-year revenue guidance by approximately $80 million at the midpoint, citing weaker Marucci performance, PVG supply disruptions, AAG upfit challenges, and softer bike demand. FOXF shareholders who lost money may have the right to seek a recovery.

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Fox Factory Holding Corp. (NASDAQ: FOXF) CFO Dennis Schemm told investors on May 7, 2026, "We are reaffirming our full year guide for 2026." The Company has since cut its FY2026 net sales outlook to $1.35–$1.38 billion, down from $1.42–$1.47 billion. FOXF shares fell following the announcement. Shareholders who lost money on FOXF are encouraged to submit their losses for a free review or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

On May 7, 2026, CFO Dennis Schemm tied the reaffirmation of Fox Factory's FY2026 guidance to "our first quarter performance and the continued execution of our cost-out programs." On the same call, CEO Michael Dennison stated that first-quarter changes "should enable many of the other work streams to drive top and bottom line improvements towards the end of this year." On October 16, 2026, however, the Company lowered its FY2026 net sales guidance to $1.35–$1.38 billion, reducing the midpoint to $1.365 billion—$80 million below the previously stated midpoint of $1.445 billion.

When Fox Factory lowered its FY2026 outlook, it cited several headwinds, including the timing of the Marucci divestiture, a supply disruption at PVG, operating challenges at AAG, and softer bicycle sales. Levi & Korsinsky is investigating potential securities law violations on behalf of FOXF shareholders.

FOXF investors who suffered losses can request a free evaluation of your FOXF losses, or call (212) 363-7500 to speak with the firm.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the FOXF Investigation

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Fox Factory Holding Corp. made materially false or misleading statements regarding its FY2026 financial guidance. On October 16, 2026, the Company disclosed preliminary third-quarter results below its own guidance and reduced its full-year 2026 outlook, following which FOXF shares declined.

Q: When did Fox Factory allegedly mislead investors?A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do FOXF investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my FOXF shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought FOXF and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

Tel: (212) 363-7500

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP

Share this article

Corgi Insurance hires former Chubb Underwriting AVP James Kullman

SAN FRANCISCO, Oct. 16, 2026 /PRNewswire/ -- Corgi Insurance today announced the appointment of James Kullman as Head of Underwriting, North America. Kullman brings nearly 15 years of experience in commercial insurance underwriting and management, with expertise spanning risk assessment, portfolio management, product development and underwriting strategy.

Kullman joins Corgi from Chubb, where he most recently served as Assistant Vice President and Pacific North Region Underwriting Manager for North American Small and Lower Middle Market. His previous experience includes underwriting roles at CNA Insurance, The Hartford and Liberty Mutual, where he worked across construction, middle-market accounts and property and casualty insurance.

At Corgi, Kullman will lead efforts to advance commercial underwriting across North America, leveraging AI to improve risk selection, develop underwriting guidelines, strengthen portfolio management and support regulatory compliance. His role will focus on combining traditional underwriting expertise with AI-assisted tools and processes to help make commercial insurance more efficient, responsive and accessible.

"Commercial insurance has relied on many of the same processes for decades. AI gives us an opportunity to rethink how underwriting works, from how we evaluate risk to how quickly we can deliver a quote," said James Kullman, Head of Underwriting, North America at Corgi. "I'm excited to bring my experience in traditional underwriting to a team that is building new technology and infrastructure for the industry."

Corgi is building a full-stack insurance platform that combines proprietary underwriting technology with in-house claims handling and insurance infrastructure. By bringing underwriting expertise and AI together, the company aims to help businesses get coverage more efficiently while maintaining disciplined risk selection and strong underwriting standards.

Kullman's appointment reflects Corgi's continued investment in insurance expertise as it expands its commercial insurance capabilities and builds technology designed to modernize how carriers, brokers and customers interact.

About Corgi Insurance

Corgi is an AI-native insurance carrier built for high-growth companies. The company combines proprietary underwriting technology, in-house claims handling, and modern insurance infrastructure to deliver coverage built for the way businesses operate today.

Media Contact:

Corgi Media

[email protected] 

SOURCE Corgi

Share this article

SAN DIEGO, Oct. 16, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Gildan Activewear Inc. (NYSE: GIL) publicly traded securities between February 19, 2025 and June 15, 2026, inclusive (the "Class Period"), have until December 14, 2026 to seek appointment as lead plaintiff of the Gildan Activewear class action lawsuit. Captioned Cortez v. Gildan Activewear Inc., No. 26-cv-02126 (N.D.N.Y.), the Gildan Activewear class action lawsuit charges Gildan Activewear and certain of Gildan Activewear's top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Gildan Activewear class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-gildan-activewear-inc-class-action-lawsuit-gil.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Gildan Activewear manufactures and sells various apparel products.

The Gildan Activewear class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Gildan Activewear did not have adequate internal controls; (ii) Gildan Activewear used channel stuffing to create an appearance of revenue; and (iii) as a result, defendants' statements about Gildan Activewear's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

On June 16, 2026, Jehoshaphat Research published a report in which it allegedly announced that it had a short position in Gildan Activewear securities. That same day, Investing.com published an article summarizing the report entitled "Gildan Activewear stock falls after short seller report." The article stated that the "short seller alleged that Gildan [Activewear] has been 'stuffing' its distributors and customers with excess product beyond underlying end user demand. According to the report, this has created a product overhang worth approximately $500 million, which contrasts with consensus forecasts for 2026." On this news, the price of Gildan Activewear's NYSE-listed shares declined nearly 19%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Gildan Activewear publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Gildan Activewear class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Gildan Activewear class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Gildan Activewear class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Gildan Activewear class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices. 

SOURCE Robbins Geller Rudman & Dowd LLP

Share this article

LAS VEGAS, Oct. 16, 2026 /PRNewswire/ -- Michael J. Bonner, co-managing shareholder of the Las Vegas office of global law firm Greenberg Traurig, LLP, was presented with the Distinguished Leadership Award by the Las Vegas Regional Economic Partnership (LVREP), formerly the Las Vegas Global Economic Alliance (LVGEA).

The Distinguished Leadership Award celebrates an individual whose leadership, vision, and influence have made a lasting impact on Southern Nevada's economic landscape, according to the organization. The LVREP bestowed the honor upon Bonner during its inaugural PERSPECTIVE Awards Dinner Oct. 15, which brought together business leaders, elected officials, and community stakeholders to celebrate the individuals, organizations, and projects driving Southern Nevada's economic growth while highlighting the vision and leadership shaping the region's future, according to its website. At the awards dinner, the new name for the former LVGEA, the Las Vegas Regional Economic Partnership, was unveiled.

Bonner was nominated by Las Vegas Co-Managing Shareholder Jim Mace, who described Bonner as someone who leads with purpose while inspiring collaboration and championing inclusive growth. At the dinner, Bonner was presented with the award by Litigation Shareholder Joel E. Tasca, who is also based in the firm's Las Vegas office.

Bonner has built a distinguished career defined by leadership, collaboration, and service. A highly respected corporate lawyer who counsels companies, boards, and gaming industry clients on complex business and governance matters, Bonner has played a pivotal role in strengthening Southern Nevada's civic and economic landscape. Through his leadership of business, educational, and community organizations, he has brought together diverse stakeholders, championed opportunities for future leaders, and helped drive inclusive growth across the region. His ability to pair professional excellence with a deep commitment to community impact embodies the spirit of the Distinguished Leadership Award.

The LVREP is a public-private partnership dedicated to connecting and championing Southern Nevada's economic future through intentional business attraction, expansion, and regional connectivity. Rooted in the region's world-class hospitality and powered by innovation, Southern Nevada continues to position itself as a global leader in reinvention and opportunity for all. LVREP has been designated as one of eight Regional Development Authorities (RDA) in Nevada by the Governor's Office of Economic Development (GOED) for 2026-2027, according to the organization.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

SOURCE Greenberg Traurig, LLP

Share this article